Comparing Urine Levels of BLCA-4 Nuclear Matrix Protein in Patients with Bladder Cancer and Non-bladder Cancer

Overview

Journal Int J Physiol Pathophysiol Pharmacol

Date 2020 Jan 30

PMID 31993104

Citations 11

Authors

Ali Alavi

Mohammad-Hosein Izadpanahi

Leila Haghshenas

Romina Faridizad

Mohammad-Javad Eslami

Keyvan Ghadimi

Affiliations

Soon will be listed here.

Abstract

Background: The molecular mechanism of bladder cancer is yet not fully understood. Aim of this study was to compare the levels of BLCA-4 nuclear matrix protein in the urine of patients with bladder cancer and non-affected individuals.

Materials And Method: The current cross sectional study was conducted on 45 patients with bladder cancer and 45 patients without bladder cancer who were referred to Alzahra Hospital of Isfahan, Iran in 2017. BCLA-4 Urinary Marker was measured in urine of the patients and individuals. Also correlation between the urine levels of BCLA-4 and other variables were evaluated.

Results: The urine levels of BLCA-4 in the patients with bladder cancer was significantly higher than non-bladder cancer group (P<0.001). There was no significant relationship between urine levels of BLCA-4 with tumor stage and size (P>0.05).

Conclusion: The present study indicated that high urine levels of BLCA-4 was presented in patients with bladder cancer and this tumor marker has a high capability for early diagnosis of the disease, which can be used for screening and follow-up of bladder cancer.

Citing Articles

Current look at the most promising proteomic and glycomic biomarkers of bladder cancer.

Harsanyi S, Kianickova K, Katrlik J, Danisovic L, Ziaran S J Cancer Res Clin Oncol. 2024; 150(2):96.

PMID: 38372785 PMC: 10876723. DOI: 10.1007/s00432-024-05623-7.

Effect of Pioglitazone on Nonalcoholic Fatty Liver Disease in Morbid Obese Patients; a Randomized Controlled Trial.

Sayadishahraki M, Mirfendereski S, Kachuei A, Rafiee Zadeh A, Mirghaderi A Adv Biomed Res. 2023; 12:27.

PMID: 37057246 PMC: 10086638. DOI: 10.4103/abr.abr_354_21.

Evaluation of the Relative Frequency of Epstein-Barr Virus Infection in Patients with Recurrent Breast Cancer Compared with Patients with Nonrecurrent Breast Cancer.

Eshraghi Samani R, Safaee M, Nematollahi P, Amraei B Adv Biomed Res. 2023; 12:34.

PMID: 37057233 PMC: 10086641. DOI: 10.4103/abr.abr_381_21.

Incidence of steal syndrome following arteriovenous fistula and arteriovenous graft.

Saroukhani A, Rafiee Zadeh A, Ahmadi S Int J Burns Trauma. 2022; 12(3):121-126.

PMID: 35891975 PMC: 9301160.

Proteomics for Early Detection of Non-Muscle-Invasive Bladder Cancer: Clinically Useful Urine Protein Biomarkers.

Ahn J, Kang C, Kim E, Kim A, Kim A Life (Basel). 2022; 12(3).

PMID: 35330146 PMC: 8950253. DOI: 10.3390/life12030395.

References

Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J . EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol. 2011; 59(6):997-1008. DOI: 10.1016/j.eururo.2011.03.017. View

Lotan Y, Roehrborn C . Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology. 2003; 61(1):109-18; discussion 118. DOI: 10.1016/s0090-4295(02)02136-2. View

Schwalb D, Herr H, Fair W . The management of clinically unconfirmed positive urinary cytology. J Urol. 1993; 150(6):1751-6. DOI: 10.1016/s0022-5347(17)35886-x. View

Zhao Q, Shen W, Chen Z, Zhou Z, Ji H . High expression level of BLCA-4 correlates with poor prognosis in human bladder cancer. Int J Clin Exp Pathol. 2012; 5(5):422-7. PMC: 3396067. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1):5-29. DOI: 10.3322/caac.21254. View

Cai Q, Wu Y, Guo Z, Gong R, Tang Y, Yang K . Urine BLCA-4 exerts potential role in detecting patients with bladder cancers: a pooled analysis of individual studies. Oncotarget. 2015; 6(35):37500-10. PMC: 4741944. DOI: 10.18632/oncotarget.6061. View

Al-Sukhun S, Hussain M . Molecular biology of transitional cell carcinoma. Crit Rev Oncol Hematol. 2003; 47(2):181-93. DOI: 10.1016/s1040-8428(03)00081-7. View

Witjes J, Hendricksen K . Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results. Eur Urol. 2007; 53(1):45-52. DOI: 10.1016/j.eururo.2007.08.015. View

Flaig T, Spiess P, Agarwal N, Bangs R, Boorjian S, Buyyounouski M . NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. J Natl Compr Canc Netw. 2018; 16(9):1041-1053. DOI: 10.6004/jnccn.2018.0072. View

10.

KANTOR A, Hartge P, Hoover R, NARAYANA A, Sullivan J, Fraumeni Jr J . Urinary tract infection and risk of bladder cancer. Am J Epidemiol. 1984; 119(4):510-5. DOI: 10.1093/oxfordjournals.aje.a113768. View

11.

Whelan P, Britton J, Dowell A . Three-year follow-up of bladder tumours found on screening. Br J Urol. 1993; 72(6):893-6. DOI: 10.1111/j.1464-410x.1993.tb16292.x. View

12.

Feng C, Wang P, Guan M, Jiang H, Wen H, Ding Q . Urinary BLCA-4 is highly specific for detection of bladder cancer in Chinese Han population and is related to tumour invasiveness. Folia Biol (Praha). 2012; 57(6):242-7. View

13.

Jones C, Athanasiou T . Summary receiver operating characteristic curve analysis techniques in the evaluation of diagnostic tests. Ann Thorac Surg. 2004; 79(1):16-20. DOI: 10.1016/j.athoracsur.2004.09.040. View

14.

Burger M, Catto J, Dalbagni G, Grossman H, Herr H, Karakiewicz P . Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2012; 63(2):234-41. DOI: 10.1016/j.eururo.2012.07.033. View

15.

Walter S . Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Stat Med. 2002; 21(9):1237-56. DOI: 10.1002/sim.1099. View

16.

Konety B, Nguyen T, Brenes G, Sholder A, Lewis N, Bastacky S . Clinical usefulness of the novel marker BLCA-4 for the detection of bladder cancer. J Urol. 2000; 164(3 Pt 1):634-9. DOI: 10.1097/00005392-200009010-00004. View

17.

Santoni M, Catanzariti F, Minardi D, Burattini L, Nabissi M, Muzzonigro G . Pathogenic and Diagnostic Potential of BLCA-1 and BLCA-4 Nuclear Proteins in Urothelial Cell Carcinoma of Human Bladder. Adv Urol. 2012; 2012:397412. PMC: 3395315. DOI: 10.1155/2012/397412. View

18.

Case R, HOSKER M, McDonald D, Pearson J . Tumours of the urinary bladder in workmen engaged in the manufacture and use of certain dyestuff intermediates in the British chemical industry. I. The role of aniline, benzidine, alpha-naphthylamine, and beta-naphthylamine. Br J Ind Med. 1954; 11(2):75-104. PMC: 1037533. DOI: 10.1136/oem.11.2.75. View